Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020
Expansion of leading biomarker and bioanalysis company enhances bioanalytical solutions for targeted radiopharmaceuticals
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
Leading pharma companies are achieving rapid, large-scale performance improvements using a multifaceted approach that realizes short-term gains & builds long-term capabilities at the same time
The latest certification endorses product for cold chain monitoring across 194 WHO member countries
As part of large-scale clinical studies prior to market introduction, the AI software has now gone into clinical test with patients, so-called first-in-human applications
City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours
The centres will be located in Tier I and Tier II cities
The curriculum has been curated for General Physicians working in Clinikk
Bempedoic Acid administered as a 180-mg dose, is approved by the USFDA and European Union for the treatment of hypercholesterolemia
Subscribe To Our Newsletter & Stay Updated
